Postprandial plasma glucose concentrations are an important contributor to glycemic
control. There is evidence suggesting that postprandial hyperglycemia may be an …

Aims To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian
patients with type 2 diabetes insufficiently controlled on basal insulin±sulfonylurea. Methods …

Abstract Introduction “Incretin-based” therapies, such as the glucagon-like peptide-1 (GLP-1)
receptor agonists, represent a major advance in type 2 diabetes mellitus (T2DM) treatment …

Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in
type 2 diabetes insufficiently controlled on metformin. Methods In this 28‐day, randomized …

OBJECTIVE To examine the efficacy and safety of lixisenatide (20 μg once daily,
administered before the morning or evening meal) as add-on therapy in patients with type 2 …

Objectives To determine the effects of lixisenatide, a new once-daily (QD) glucagon-like
peptide-1 receptor agonist, on postprandial glucose (PPG) and gastric emptying, and the …

Aims To compare the efficacy and safety of once‐daily prandial lixisenatide with placebo in
type 2 diabetes mellitus (T2DM) insufficiently controlled by pioglitazone±metformin. Methods …

Background This study assessed the efficacy and safety of the once‐daily glucagon‐like
peptide‐1 receptor agonist, lixisenatide, in Asian patients with type 2 diabetes mellitus …

Background The objective of this article is to evaluate the pharmacokinetics, efficacy and
safety of lixisenatide (subcutaneous injection) in elderly (≥ 65 years old) and very elderly …

In addition to promoting glucose homeostasis, glucagon-like peptide 1 (GLP-1) has a
number of extra-pancreatic effects that regulate appetite and body weight. GLP-1 delays …